IP Verse

Treatment Of Cancer Using Chimeric Antigen Receptor - EP3119423

The patent EP3119423 was granted to Novartis on Dec 14, 2022. The application was originally filed on Mar 13, 2015 under application number EP15712503A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3119423

NOVARTIS
Application Number
EP15712503A
Filing Date
Mar 13, 2015
Status
Granted And Under Opposition
Nov 11, 2022
Grant Date
Dec 14, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONSep 14, 2023MEWBURN ELLISADMISSIBLE
PATENT BOUTIQUESep 14, 2023-ADMISSIBLE
MURGITROYDSep 13, 2023-ADMISSIBLE

Patent Citations (319) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2006US22995
DESCRIPTIONCA2523449
DESCRIPTIONEP0090505
DESCRIPTIONEP0239400
DESCRIPTIONEP0346087
DESCRIPTIONEP0519596
DESCRIPTIONEP0592106
DESCRIPTIONEP0754230
DESCRIPTIONEP0805871
DESCRIPTIONEP1013761
DESCRIPTIONEP1866339
DESCRIPTIONEP1947183
DESCRIPTIONEP2322550
DESCRIPTIONEP2514766
DESCRIPTIONUS2002004587
DESCRIPTIONUS2002076406
DESCRIPTIONUS2002103345
DESCRIPTIONUS2003207346
DESCRIPTIONUS2003211078
DESCRIPTIONUS2004047858
DESCRIPTIONUS2004101519
DESCRIPTIONUS2004219643
DESCRIPTIONUS2004220388
DESCRIPTIONUS2004242847
DESCRIPTIONUS2005003403
DESCRIPTIONUS2005004352
DESCRIPTIONUS2005042664
DESCRIPTIONUS2005048617
DESCRIPTIONUS2005069552
DESCRIPTIONUS2005079170
DESCRIPTIONUS2005100543
DESCRIPTIONUS2005101624
DESCRIPTIONUS2005129701
DESCRIPTIONUS2005136049
DESCRIPTIONUS2005136051
DESCRIPTIONUS2005163782
DESCRIPTIONUS2005175606
DESCRIPTIONUS2005266425
DESCRIPTIONUS2006034810
DESCRIPTIONUS2006083747
DESCRIPTIONUS2006120960
DESCRIPTIONUS2006121005
DESCRIPTIONUS2006204493
DESCRIPTIONUS2006263367
DESCRIPTIONUS2007004909
DESCRIPTIONUS2007014794
DESCRIPTIONUS2007036773
DESCRIPTIONUS2007087381
DESCRIPTIONUS2007128150
DESCRIPTIONUS2007141049
DESCRIPTIONUS2007154901
DESCRIPTIONUS2007274985
DESCRIPTIONUS2008050370
DESCRIPTIONUS2008069820
DESCRIPTIONUS2008152645
DESCRIPTIONUS2008171855
DESCRIPTIONUS2008241884
DESCRIPTIONUS2008254512
DESCRIPTIONUS2008260738
DESCRIPTIONUS2009082299
DESCRIPTIONUS2009130106
DESCRIPTIONUS2009148905
DESCRIPTIONUS2009155275
DESCRIPTIONUS2009162359
DESCRIPTIONUS2009162360
DESCRIPTIONUS2009175851
DESCRIPTIONUS2009175867
DESCRIPTIONUS2009232811
DESCRIPTIONUS2009234105
DESCRIPTIONUS2009263392
DESCRIPTIONUS2009274649
DESCRIPTIONUS2009297529
DESCRIPTIONUS2009304718
DESCRIPTIONUS2009311181
DESCRIPTIONUS2010028330
DESCRIPTIONUS2010150910
DESCRIPTIONUS2010247521
DESCRIPTIONUS2010297138
DESCRIPTIONUS2011081311
DESCRIPTIONUS2011158957
DESCRIPTIONUS2011268656
DESCRIPTIONUS2012009181
DESCRIPTIONUS2012039906
DESCRIPTIONUS2012060230
DESCRIPTIONUS2012114649
DESCRIPTIONUS2012141413
DESCRIPTIONUS2012177598
DESCRIPTIONUS2012276046
DESCRIPTIONUS2012288506
DESCRIPTIONUS2012321667
DESCRIPTIONUS2013101607
DESCRIPTIONUS2013156774
DESCRIPTIONUS2013295007
DESCRIPTIONUS2014004124
DESCRIPTIONUS2014068797
DESCRIPTIONUS2014271618
DESCRIPTIONUS3929992
DESCRIPTIONUS4433059
DESCRIPTIONUS4444878
DESCRIPTIONUS4816567
DESCRIPTIONUS4851332
DESCRIPTIONUS504048
DESCRIPTIONUS5199942
DESCRIPTIONUS5225539
DESCRIPTIONUS5273743
DESCRIPTIONUS5350674
DESCRIPTIONUS5399346
DESCRIPTIONUS5530101
DESCRIPTIONUS5534254
DESCRIPTIONUS5565332
DESCRIPTIONUS5580859
DESCRIPTIONUS5582996
DESCRIPTIONUS5585089
DESCRIPTIONUS5585362
DESCRIPTIONUS5589466
DESCRIPTIONUS5591828
DESCRIPTIONUS5635602
DESCRIPTIONUS5637481
DESCRIPTIONUS5665772
DESCRIPTIONUS5731168
DESCRIPTIONUS5766886
DESCRIPTIONUS5777084
DESCRIPTIONUS5786464
DESCRIPTIONUS5837242
DESCRIPTIONUS5837821
DESCRIPTIONUS5843674
DESCRIPTIONUS5844094
DESCRIPTIONUS5858358
DESCRIPTIONUS5864019
DESCRIPTIONUS5869620
DESCRIPTIONUS5883223
DESCRIPTIONUS5910573
DESCRIPTIONUS5932448
DESCRIPTIONUS5952484
DESCRIPTIONUS5959083
DESCRIPTIONUS5989830
DESCRIPTIONUS6004973
DESCRIPTIONUS6005079
DESCRIPTIONUS6015815
DESCRIPTIONUS6111090
DESCRIPTIONUS6114148
DESCRIPTIONUS6120766
DESCRIPTIONUS6239259
DESCRIPTIONUS6294353
DESCRIPTIONUS6326193
DESCRIPTIONUS6331415
DESCRIPTIONUS6333396
DESCRIPTIONUS6352694
DESCRIPTIONUS6407213
DESCRIPTIONUS6437098
DESCRIPTIONUS6476198
DESCRIPTIONUS6511663
DESCRIPTIONUS6528481
DESCRIPTIONUS6534055
DESCRIPTIONUS6548640
DESCRIPTIONUS6670453
DESCRIPTIONUS6692964
DESCRIPTIONUS6703199
DESCRIPTIONUS6743896
DESCRIPTIONUS6797514
DESCRIPTIONUS6809185
DESCRIPTIONUS6833441
DESCRIPTIONUS6846911
DESCRIPTIONUS6867041
DESCRIPTIONUS6887466
DESCRIPTIONUS6905680
DESCRIPTIONUS6905681
DESCRIPTIONUS6905874
DESCRIPTIONUS7025962
DESCRIPTIONUS7067318
DESCRIPTIONUS7090843
DESCRIPTIONUS7091213
DESCRIPTIONUS7129330
DESCRIPTIONUS7132255
DESCRIPTIONUS7144575
DESCRIPTIONUS7172869
DESCRIPTIONUS7175843
DESCRIPTIONUS7183076
DESCRIPTIONUS7232566
DESCRIPTIONUS7253263
DESCRIPTIONUS7410640
DESCRIPTIONUS7521056
DESCRIPTIONUS7527787
DESCRIPTIONUS7534866
DESCRIPTIONUS7612181
DESCRIPTIONUS7618632
DESCRIPTIONUS7635753
DESCRIPTIONUS7727950
DESCRIPTIONUS7749719
DESCRIPTIONUS7812135
DESCRIPTIONUS7915391
DESCRIPTIONUS7943743
DESCRIPTIONUS8008449
DESCRIPTIONUS8080650
DESCRIPTIONUS8124084
DESCRIPTIONUS8207308
DESCRIPTIONUS8263746
DESCRIPTIONUS8309693
DESCRIPTIONUS8344112
DESCRIPTIONUS8354509
DESCRIPTIONUS8362211
DESCRIPTIONUS8388967
DESCRIPTIONUS8440798
DESCRIPTIONUS8501415
DESCRIPTIONUS8586023
DESCRIPTIONUS8591886
DESCRIPTIONUS8603466
DESCRIPTIONUS8609089
DESCRIPTIONUS8697359
DESCRIPTIONUS8771945
DESCRIPTIONUS8795965
DESCRIPTIONUS8865406
DESCRIPTIONUS8871445
DESCRIPTIONUSRE44768E
DESCRIPTIONWO0006605
DESCRIPTIONWO0103720
DESCRIPTIONWO0112812
DESCRIPTIONWO0114387
DESCRIPTIONWO0129058
DESCRIPTIONWO0196584
DESCRIPTIONWO02072635
DESCRIPTIONWO03014161
DESCRIPTIONWO03062401
DESCRIPTIONWO03064383
DESCRIPTIONWO2004081051
DESCRIPTIONWO2004087758
DESCRIPTIONWO2005007190
DESCRIPTIONWO2005035577
DESCRIPTIONWO2005055808
DESCRIPTIONWO2005115451
DESCRIPTIONWO2006020258
DESCRIPTIONWO2006083289
DESCRIPTIONWO2006106905
DESCRIPTIONWO2006121168
DESCRIPTIONWO2006122806
DESCRIPTIONWO2006125481
DESCRIPTIONWO2006138315
DESCRIPTIONWO2007005874
DESCRIPTIONWO2007024715
DESCRIPTIONWO2007044729
DESCRIPTIONWO2007044887
DESCRIPTIONWO2007067992
DESCRIPTIONWO2007095338
DESCRIPTIONWO2007110205
DESCRIPTIONWO2007133822
DESCRIPTIONWO2007137760
DESCRIPTIONWO2008119353
DESCRIPTIONWO2008146911
DESCRIPTIONWO2009021754
DESCRIPTIONWO2009068630
DESCRIPTIONWO2009089004
DESCRIPTIONWO2009101611
DESCRIPTIONWO2009104019
DESCRIPTIONWO2009114335
DESCRIPTIONWO2010003118
DESCRIPTIONWO2010019570
DESCRIPTIONWO2010027827
DESCRIPTIONWO2010033866
DESCRIPTIONWO2010051043
DESCRIPTIONWO2010077634
DESCRIPTIONWO2010114484
DESCRIPTIONWO2010125571
DESCRIPTIONWO2010129304
DESCRIPTIONWO2011028683
DESCRIPTIONWO2011051726
DESCRIPTIONWO2011066342
DESCRIPTIONWO2011076922
DESCRIPTIONWO2011090754
DESCRIPTIONWO2011131746
DESCRIPTIONWO2011159847
DESCRIPTIONWO2011160119
DESCRIPTIONWO2012006552
DESCRIPTIONWO2012007926
DESCRIPTIONWO2012033885
DESCRIPTIONWO2012079000
DESCRIPTIONWO2012135854
DESCRIPTIONWO2012138475
DESCRIPTIONWO2012163805
DESCRIPTIONWO2013006490
DESCRIPTIONWO2013023184
DESCRIPTIONWO2013039954
DESCRIPTIONWO2013040371
DESCRIPTIONWO2013054331
DESCRIPTIONWO2013060867
DESCRIPTIONWO2013061273
DESCRIPTIONWO2013074916
DESCRIPTIONWO2013082366
DESCRIPTIONWO2013085552
DESCRIPTIONWO2013123061
DESCRIPTIONWO2013126712
DESCRIPTIONWO2013165940
DESCRIPTIONWO2013192294
DESCRIPTIONWO2014022332
DESCRIPTIONWO2014055442
DESCRIPTIONWO2014055657
DESCRIPTIONWO2014059251
DESCRIPTIONWO2014110591
DESCRIPTIONWO9103493
DESCRIPTIONWO9109967
DESCRIPTIONWO9317105
DESCRIPTIONWO9323537
DESCRIPTIONWO9404678
DESCRIPTIONWO9409010
DESCRIPTIONWO9409131
DESCRIPTIONWO9412625
DESCRIPTIONWO9509917
DESCRIPTIONWO9514023
DESCRIPTIONWO9516691
DESCRIPTIONWO9637621
DESCRIPTIONWO9641807
DESCRIPTIONWO9802441
DESCRIPTIONWO9915530
DESCRIPTIONWO9920758
DESCRIPTIONWO9940196
DESCRIPTIONWO9952552
DESCRIPTIONWO9964460
EXAMINATIONWO2014145252
OPPOSITIONWO2014145252
OPPOSITIONWO2015142675

Non-Patent Literature (NPL) Citations (26) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- FATEMEH RAHIMI JAMNANI ET AL, "T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENERAL SUBJECTS, (20140101), vol. 1840, no. 1, doi:10.1016/j.bbagen.2013.09.029, ISSN 0304-4165, pages 378 - 386, XP055108962
EXAMINATION- V. D. FEDOROV ET AL, "PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses", SCIENCE TRANSLATIONAL MEDICINE, (20131211), vol. 5, no. 215, doi:10.1126/scitranslmed.3006597, ISSN 1946-6234, pages 215ra172 - 215ra172, XP055210508
EXAMINATION- NAZANIN PIROOZNIA ET AL, "The Construction of Chimeric T-Cell Receptor with Spacer Base of Modeling Study of VHH and MUC1 Interaction", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, US, (20110101), vol. 2011, doi:10.1155/2011/578128, ISSN 1110-7243, pages 1 - 11, XP055369439
OPPOSITION- Anonymous, "Antibody engineering optimizing the delivery vehicle", Anonymous, Raymond M Reilly, Monoclonal antibody and peptide-targeted radiotherapy of cancer, John Wiley A Sons, Inc, (20100101), pages 10 - 12, ISBN 978-0-470-24372-5, XP093131424
OPPOSITION- Buckler David R, Darren Schofield , Daniel J Sexton , "Selection and screening of antibody Phage Display Libraries ", Buckler David R, Darren Schofield , Daniel J Sexton , Clive R Wood, Antibody Drug Discovery, Singapore, Imperial College Press, (20111201), vol. 4, pages 40 - 40, ISSN 2010-1422, ISBN 13-978-1-84816-628-8, XP093131413
OPPOSITION- Khaleghi Sepideh, Rahbarizadeh Fatemeh, Ahmadvand Davoud, Rasaee Mohammad J., Pognonec Philippe, "A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells", International Journal of hematology, NL , (20120401), vol. 95, no. 4, doi:10.1007/s12185-012-1037-6, ISSN 0925-5710, pages 434 - 444, XP093131435
OPPOSITION- Fatemeh Rahimi Jamnani, Fatemeh Rahbarizadeh, Mohammad Ali Shokrgozar, Fereidoun Mahboudi, Davoud Ahmadvand, Zahra Sharifzadeh, Ladan Parhamifar, S. Moein Moghimi, "T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy", Biochimica et Biophysica Acta (BBA) - General Subjects, Elsevier, (20140101), vol. 1840, no. 1, doi:10.1016/j.bbagen.2013.09.029, ISSN 03044165, pages 378 - 386, XP055108962
OPPOSITION- Sharifzadeh Zahra; Rahbarizadeh Fatemeh; Shokrgozar Mohammad A.; Ahmadvand Davoud; Mahboudi Fereidoun; Jamnani Fatemeh Rahimi; Moghimi S. Moein, "Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents", Cancer letters, NEW YORK, NY, US, US , (20120816), vol. 334, no. 2, doi:10.1016/j.canlet.2012.08.010, ISSN 0304-3835, pages 237 - 244, XP028555132
OPPOSITION- Farnoush Jafari Iri-Sofla; Fatemeh Rahbarizadeh; Davoud Ahmadvand; Mohammad J. Rasaee;, "Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase", Experimental Cell Research, AMSTERDAM, NL , (20110822), vol. 317, no. 18, doi:10.1016/j.yexcr.2011.08.015, ISSN 0014-4827, pages 2630 - 2641, XP028307301
OPPOSITION- Nabil Ahmed, Vita S Salsman, Eric Yvon, Chrystal U Louis, Laszlo Perlaky, Winfried S Wels, Meghan K Dishop, Eugenie E Kleinerman, Martin Pule, Cliona M Rooney, Helen E Heslop, Stephen Gottschalk, "Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression", Molecular Therapy, No longer published by Elsevier, (20091001), vol. 17, no. 10, doi:10.1038/mt.2009.133, ISSN 15250016, pages 1779 - 1787, XP055127295
OPPOSITION- Hegde M, Corder A, Chow K K, Mukherjee M, Ashoori A, Kew Y, Zhang Y J, Baskin D S, Merchant F A, Brawley V S, Byrd T T, Krebs S, Wu M F, Liu H, Heslop H E, Gottachalk S, Yvon E, Ahmed N., "Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.", Molecular Therapy, Nature Publishing Group, GB, GB , (20131101), vol. 21, no. 11, doi:10.1038/mt.2013.185, ISSN 1525-0024, pages 2087 - 2101, XP002725708
OPPOSITION- John Maher, Renier J. Brentjens, Gertrude Gunset, Isabelle Rivière, Michel Sadelain, "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20020101), vol. 20, no. 1, doi:10.1038/nbt0102-70, ISSN 1087-0156, pages 70 - 75, XP055552837
OPPOSITION- Adrienne H Long, Haso Waleed M, Shern Jack F, Wanhainen Kelsey M, Murgai Meera, Ingaramo Maria, Smith Jillian P, Walker Alec J, Kohler M Eric, Venkateshwara Vikas R, Kaplan Rosandra N, Patterson George H, Fry Terry J, Orentas Rimas J, Mackall Crystal L, "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors", Nature Medicine, Nature Publishing Group US, New York, New York, (20150601), vol. 21, no. 6, doi:10.1038/nm.3838, ISSN 1078-8956, pages 581 - 590, XP055278553
OPPOSITION- Hollyman Daniel, Stefanski Jolanta, Przybylowski Mark, Bartido Shirley, Borquez-Ojeda Oriana, Taylor Clare, Yeh Raymond, Capacio Vanessa, Olszewska Malgorzata, Hosey James, Sadelain Michel, Brentjens Renier J., Rivière Isabelle, "Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy", Journal of Immunotherapy, US , (20090201), vol. 32, no. 2, doi:10.1097/CJI.0b013e318194a6e8, ISSN 1524-9557, pages 1 - 22, XP093131401
OPPOSITION- Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K. Brenner, "Design and development of therapies using chimeric antigen receptor‐expressing T cells", Immunological Reviews, Wiley-Blackwell Publishing, Inc., US, US , (20131213), vol. 257, no. 1, doi:10.1111/imr.12131, ISSN 0105-2896, pages 107 - 126, XP071455751
OPPOSITION- Fedorov Victor D., Themeli Maria, Sadelain Michel, "PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses", SCIENCE TRANSLATIONAL MEDICINE, American Association for the Advancement of Science, (20131211), vol. 5, no. 215, doi:10.1126/scitranslmed.3006597, ISSN 1946-6234, pages 1 - 25, XP093131393
OPPOSITION- Fedorov Victor D., Themeli Maria, Sadelain Michel, "PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses", Science Translation Medicine, (20131211), vol. 5, no. 215, doi:10.1126/scitranslmed.3006597, ISSN 1946-6234, pages 1 - 25, XP093131393
OPPOSITION- Marc Cartellieri, Michael Bachmann, Anja Feldmann, Claudia Bippes, Slava Stamova, Rebekka Wehner, Achim Temme, Marc Schmitz, "Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer", Journal of Biomedicine and Biotechnology, (20100101), vol. 21, no. 4, doi:10.1155/2010/956304, ISSN 11107243, pages 427 - 13, XP055206629
OPPOSITION- Nazanin Pirooznia, Et Al, "The Construction of Chimeric T-Cell Receptor with Spacer Base of Modeling Study of VHH and MUC1 Interaction", Journal of Biomedicine and Biotechnology, Hindawi Pub. Corp., (20110101), vol. 2011, doi:10.1155/2011/578128, ISSN 1110-7243, pages 1 - 11, XP055369439
OPPOSITION- S. Kong, S. Sengupta, B. Tyler, A. J. Bais, Q. Ma, S. Doucette, J. Zhou, A. Sahin, B. S. Carter, H. Brem, R. P. Junghans, P. Sampath, "Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells", Clinical Cancer Research, Association for Cancer Research, US, US, (20121101), vol. 18, no. 21, doi:10.1158/1078-0432.CCR-12-0319, ISSN 1078-0432, pages 5949 - 5960, XP055242650
OPPOSITION- Pouya Safarzadeh Kozani;Abdolhossein Naseri;SeyedMohamadJavad Mirarefin;Faeze Salem;Mojtaba Nikbakht;Sahar Evazi Bakhshi;Pooria Safarzadeh Kozani, "Nanobody-based CAR-T cells for cancer immunotherapy", Biomarker Research, BioMed Central Ltd, London, UK, London, UK, (20220425), vol. 10, no. 1, doi:10.1186/s40364-022-00371-7, pages 1 - 18, XP021302554
OPPOSITION- Duong Connie Pm; Westwood Jennifer A; Berry Linda J; Darcy Phillip K; Kershaw Michael H, "Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.", Immunotherapy, Future Medicine, London, London , (20110101), vol. 3, no. 1, doi:10.2217/imt.10.81, ISSN 1750-7448, pages 33 - 48, XP008175032
OPPOSITION- Rahbarizadeh Fatemeh; Ahmadvand Davoud; Sharifzadeh Zahra, "Nanobody; an old concept and new vehicle for immunotargeting.", IMMUNOLOGICAL INVESTIGATIONS., Informa Healthcare, US, US , (20110101), vol. 40, no. 3, doi:10.3109/08820139.2010.542228, ISSN 0882-0139, pages 299 - 338, XP009146391
OPPOSITION- Fukuda Natsuki, Noi Kentaro, Weng Lidong, Kobashigawa Yoshihiro, Miyazaki Hiromi, Wakeyama Yukari, Takaki Michiyo, Nakahara Yusuke, Tatsuno Yuka, Uchida-Kamekura Makiyo, Suwa Yoshiaki, Sato Takashi, Ichikawa-Tomikawa Naoki, Nomizu Motoyoshi, Fujiwara Yukio, Ohsaka Fumina, Saitoh Takashi, Maenaka Katsumi, Kumeta Hiroyuki, Shinya Shoko, Kojima Chojiro, Ogura Teru, Morioka Hiroshi, "Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion", Molecules, SPRINGER VERLAG, BERLIN, DE, DE , (20171010), vol. 22, no. 10, doi:10.3390/molecules22101695, ISSN 1433-1373, page 1695, XP093182933
OPPOSITION- Diana Gil, Schrum Adam G., "Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments", Advances in Bioscience and Biotechnology, (20130101), vol. 4, doi:10.4236/abb.2013.44A011, ISSN 2156-8456, pages 73 - 84, XP055325678
OPPOSITION- Fatemeh Rahbarizadeh, Fatemeh Rahimi Jamnani and Farnoush Jafari Iri-Sofla, "Nanobody, New Agent for D17 Combating Against Breast Cancer Cells", Breast Cancer - Current and Alternative Therapeutic Modalities, (20111109), doi:10.5772/22927, ISBN 978-953-307-776-5, pages 347 - 370, XP009555499

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents